【摘要】：年齡相關(guān)性黃斑變性(age-related macular degeneration,AMD)是60歲以上老年人視力不可逆性損傷的首要原因,其發(fā)病率隨著年齡的增加而增高。干性AMD是AMD最常見的一種類型,它會(huì)引起視力逐漸下降,病情進(jìn)展非常緩慢,干性AMD病程發(fā)展到晚期時(shí),出現(xiàn)地圖樣萎縮,中心視力也會(huì)缺失。目前普遍認(rèn)為其發(fā)病機(jī)制主要由慢性炎癥損傷、氧化應(yīng)激損傷、脂褐質(zhì)沉積及玻璃膜疣形成、脈絡(luò)膜血供不足等引起,針對(duì)病因治療是當(dāng)前主要治療方案,但一些新的治療方法如番紅花酸、姜黃色素、睫狀神經(jīng)營(yíng)養(yǎng)因子、納米二氧化鈰和人單克隆抗體、光感受器及干細(xì)胞移植等目前均用于治療干性AMD。本文就干性AMD治療的研究進(jìn)展進(jìn)行綜述。
[Abstract]:Age-related macular degeneration (age-related macular) is the leading cause of irreversible visual impairment in the elderly over 60 years old, and its incidence increases with the increase of age. Dry AMD is one of the most common types of AMD. It can cause the visual acuity to decline gradually, and the progress of the disease is very slow. In the late stage of dry AMD, atrophic atrophy occurs and the central visual acuity is absent. At present, it is generally believed that its pathogenesis is mainly caused by chronic inflammatory injury, oxidative stress injury, lipofuscin deposition, vitreous warts formation, choroidal blood supply insufficiency and so on. However, some new treatments such as safflower acid, curcumin, ciliary neurotrophic factor, nano-cerium oxide and human monoclonal antibody, photoreceptor and stem cell transplantation are currently used to treat dry AMDs. This article reviews the research progress of dry AMD therapy.
【作者單位】： 重慶醫(yī)科大學(xué)附屬第一醫(yī)院 眼科學(xué)重慶重點(diǎn)實(shí)驗(yàn)室 重慶市眼科研究所;
【基金】：國(guó)家自然科學(xué)基金資助(編號(hào):81670881)~~
【分類號(hào)】：R774.5

【相似文獻(xiàn)】

相關(guān)期刊論文 前1條

1 時(shí)境遷;光感受器移植治療視網(wǎng)膜色素變性的近期隨訪[J];國(guó)外醫(yī)學(xué).眼科學(xué)分冊(cè);2003年05期

，

本文編號(hào)：2170966